Who
William Meury
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Incyte; Director, Syndax Pharmaceuticals; President and CEO, Karuna Therapeutics; EVP & Chief Commercial Officer, Allergan; EVP - Sales and Marketing, Forest Laboratories.
In numbers
- Trades disclosed
- 210
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $20.5M
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 5 Dec 2011
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —26,807 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —80,421 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —77,148 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —80,421 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —77,148 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —26,807 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $558K4,779 at $116.86 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code F | $558K4,779 at $116.86 | filing |
| 15 Apr 2026filed 17 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | —125,000 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | —125,000 at $0.00 | filing |
| 2 Jul 2025filed 2 Jul 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —108,303 at $0.00 | filing |
| 2 Jul 2025filed 2 Jul 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 2 Jul 2025filed 2 Jul 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —36,101 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —110,630 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $12.8M38,688 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $8.6M63,065 at $136.81 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $3.4M10,342 at $330.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeutics | SEC FORM 4 Code D | $6.3M19,037 at $330.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code A | —38,688 at $0.00 | filing |
News
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name William Meury; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.